Market Cap 4.41B
Revenue (ttm) 0.00
Net Income (ttm) -183.79M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.15
Volume 2,363,000
Avg Vol 3,000,866
Day's Range N/A - N/A
Shares Out 99.70M
Stochastic %K 64%
Beta 2.20
Analysts Strong Sell
Price Target $55.87

Company Profile

Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Me...

Industry: Biotechnology
Sector: Healthcare
Phone: 212 220 6633
Address:
One World Trade Center, Suite 8500, New York, United States
MichaelNaussCMT
MichaelNaussCMT Jul. 4 at 3:58 PM
$DFTX dropping hints. Now that they a ton of cash I wouldn’t be suprised to see more things researched.
1 · Reply
zcurrency
zcurrency Jul. 4 at 2:58 PM
0 · Reply
IEN
IEN Jul. 4 at 11:16 AM
0 · Reply
Rocketzz
Rocketzz Jul. 4 at 6:58 AM
1 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Jul. 3 at 2:36 PM
The $XBI is up 24.5% the last 15 trading sessions (since 6/10/2026). Investors may recall 4 years ago this time when the XBI surged 31.6% between 6/14/22 & 7/6/22. Excluding the market recovery during COVID in 2020, there's only 2 other times the XBI surged like this (15 day period ending 1/16/19 & before Thanksgiving back in 16). The XBI is almost at its record high. It traded at over $160 for 11 days back in early 2021 Recall it was May 12, 2026 when Dr. Makary resigned. Since then the FDA has reversed course on a number of bio's potential. Attached are the biggest gainers over the last 15 days (60% of more). $RGNX has overwhelmingly been the biggest winner now that they will refile for Navsunli approval in Q326. $SLS doubled again. Short interest is 36% per Seeking Alpha. At a $3B market cap SLS trades @ 4.3X Year 4 (FY30) revenue (from 1 analyst). We though we were smart when we sold SLS in the mid $4 range back in January. $DFTX reported its P3 win 6/22/26 $MRNA we have friends there :)
0 · Reply
MorganHoratio
MorganHoratio Jul. 2 at 10:12 PM
One of the strongest sectors outside of AI right now is Biotech. Neurology $DFTX Definium Therapeutics $CMPS COMPASS Pathways $DNLI Denali Therapeutics $XENE Xenon Pharmaceuticals $NBIX Neurocrine Biosciences The 70% correction trap is driving smart money into neuro-therapeutic CNS alpha pipelines. Elite institutions deploy tactical limit entries atop long-term FIB floors, lock-floating neurological monopolies. Disrupter DFTX accelerates right-side PEG defense, surging on its upsized $805M public offering and pivotal Phase 3 depression data catalysts. It pairs with psychedelic pioneer CMPS at key FIB accumulation zones, while blood-brain-barrier innovator DNLI scales following fresh Russell growth index flows. Flanking them are commercial powerhouse BIIB and pipeline leader XENE hardening their valuation ceilings. Technical compression means nothing without clinical milestones. Facing this neuro-rotation, are you buying the FIB support floors on DFTX and CMPS or resting in defensive cash?
1 · Reply
twiggs462
twiggs462 Jul. 2 at 9:03 PM
$DFTX $CMPS from a couple days ago, but nice to see the coverage https://youtu.be/srT4HUojtFU?t=277&is=5X6xYSBewrec4r2s
0 · Reply
Roaringlegend
Roaringlegend Jul. 2 at 8:42 PM
$WEN got the crowd. $BYND showed what a beaten-down name can do. $SOUN has the AI hype. But $JACK has the cleaner squeeze mechanics: tiny cap, small share count, high short interest, high days-to-cover, and strong recovery after the shakeout. Hype finds the loudest ticker first. Then it finds the best setup. $DFTX
0 · Reply
jmash
jmash Jul. 2 at 5:54 PM
$ATAI $CMPS $DFTX does explain the pop?
1 · Reply
stoxx0007
stoxx0007 Jul. 2 at 4:36 PM
0 · Reply
Latest News on DFTX
Biotech ETF Index Surges 10% After Rebalance

Jun 25, 2026, 11:31 AM EDT - 9 days ago

Biotech ETF Index Surges 10% After Rebalance

ALKS APGE DYN KLRA KYMR MANE MIRM


Definium Therapeutics rises 21.8%

2026-06-24T16:05:36.000Z - 10 days ago

Definium Therapeutics rises 21.8%


Definium Therapeutics rises 17.7%

2026-06-24T14:05:51.000Z - 10 days ago

Definium Therapeutics rises 17.7%


Definium Therapeutics 20.6M share Secondary priced at $34.00

2026-06-24T10:20:19.000Z - 10 days ago

Definium Therapeutics 20.6M share Secondary priced at $34.00


Definium Therapeutics offers to sell $500M in common stock

2026-06-22T20:18:37.000Z - 12 days ago

Definium Therapeutics offers to sell $500M in common stock


Definium Therapeutics, Inc. Announces Proposed Public Offering

Jun 22, 2026, 4:01 PM EDT - 12 days ago

Definium Therapeutics, Inc. Announces Proposed Public Offering


Definium Therapeutics rises 55.9%

2026-06-22T16:11:28.000Z - 12 days ago

Definium Therapeutics rises 55.9%


Definium Therapeutics rises 55.7%

2026-06-22T14:12:05.000Z - 12 days ago

Definium Therapeutics rises 55.7%


Definium Therapeutics Transcript: Study result

Jun 22, 2026, 8:00 AM EDT - 12 days ago

Definium Therapeutics Transcript: Study result


Definium Therapeutics Press release: Study result

Jun 22, 2026, 8:00 AM EDT - 12 days ago

Definium Therapeutics Press release: Study result


Definium Therapeutics Slides: Study result

Jun 22, 2026, 8:00 AM EDT - 12 days ago

Definium Therapeutics Slides: Study result


Definium Therapeutics Slides: Corporate presentation

Jun 22, 2026, 7:00 AM EDT - 12 days ago

Definium Therapeutics Slides: Corporate presentation


Definium Therapeutics Announces New Employee Inducement Grants

Jun 15, 2026, 4:01 PM EDT - 19 days ago

Definium Therapeutics Announces New Employee Inducement Grants


Definium Therapeutics Transcript: AGM 2026

Jun 11, 2026, 10:00 AM EDT - 23 days ago

Definium Therapeutics Transcript: AGM 2026


Definium Therapeutics Earnings Call Transcript: Q1 2026

May 7, 2026, 4:30 PM EDT - 2 months ago

Definium Therapeutics Earnings Call Transcript: Q1 2026


Definium Therapeutics Earnings release: Q1 2026

May 7, 2026, 4:30 PM EDT - 2 months ago

Definium Therapeutics Earnings release: Q1 2026


Definium Therapeutics Quarterly report: Q1 2026

May 7, 2026, 4:30 PM EDT - 2 months ago

Definium Therapeutics Quarterly report: Q1 2026


Definium Therapeutics Slides: Corporate presentation

May 7, 2026, 4:00 PM EDT - 2 months ago

Definium Therapeutics Slides: Corporate presentation


Definium Therapeutics Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 2 months ago

Definium Therapeutics Proxy statement: Proxy filing


Definium Therapeutics Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 2 months ago

Definium Therapeutics Proxy statement: Proxy filing


Definium Therapeutics Transcript: Investor Day 2026

Apr 22, 2026, 10:00 AM EDT - 2 months ago

Definium Therapeutics Transcript: Investor Day 2026


Definium Therapeutics Slides: FY 2026

Apr 22, 2026, 10:00 AM EDT - 2 months ago

Definium Therapeutics Slides: FY 2026


Psychedelic stocks rally with Trump's support

Apr 20, 2026, 8:26 AM EDT - 2 months ago

Psychedelic stocks rally with Trump's support

ATAI CMPS GHRS


Definium Therapeutics Transcript: Stifel 2026 Virtual CNS Forum

Mar 17, 2026, 3:30 PM EDT - 3 months ago

Definium Therapeutics Transcript: Stifel 2026 Virtual CNS Forum


Definium Therapeutics Earnings Call Transcript: Q4 2025

Feb 26, 2026, 4:30 PM EST - 4 months ago

Definium Therapeutics Earnings Call Transcript: Q4 2025


Definium Therapeutics Annual report: Q4 2025

Feb 26, 2026, 4:30 PM EST - 4 months ago

Definium Therapeutics Annual report: Q4 2025


Definium Therapeutics Earnings release: Q4 2025

Feb 26, 2026, 4:30 PM EST - 4 months ago

Definium Therapeutics Earnings release: Q4 2025


Definium Therapeutics Slides: Corporate presentation

Feb 26, 2026, 4:00 PM EST - 4 months ago

Definium Therapeutics Slides: Corporate presentation


Definium Therapeutics Slides: Corporate presentation

Jan 12, 2026, 2:45 PM EST - 6 months ago

Definium Therapeutics Slides: Corporate presentation


MindMed Announces New Employee Inducement Grant

Dec 15, 2025, 4:01 PM EST - 7 months ago

MindMed Announces New Employee Inducement Grant


MindMed Announces New Employee Inducement Grants

Dec 1, 2025, 4:01 PM EST - 7 months ago

MindMed Announces New Employee Inducement Grants


Definium Therapeutics Slides: Corporate Presentation

Nov 9, 2025, 6:00 PM EST - 8 months ago

Definium Therapeutics Slides: Corporate Presentation


Definium Therapeutics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 4:30 PM EST - 8 months ago

Definium Therapeutics Earnings Call Transcript: Q3 2025


Definium Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 4:30 PM EST - 8 months ago

Definium Therapeutics Quarterly report: Q3 2025


Definium Therapeutics Earnings release: Q3 2025

Nov 6, 2025, 4:30 PM EST - 8 months ago

Definium Therapeutics Earnings release: Q3 2025


MindMed Reports Q3 2025 Financial Results and Business Updates

Nov 6, 2025, 4:01 PM EST - 8 months ago

MindMed Reports Q3 2025 Financial Results and Business Updates


Definium Therapeutics Slides: Corporate Presentation

Nov 6, 2025, 7:00 AM EST - 8 months ago

Definium Therapeutics Slides: Corporate Presentation


MindMed to Participate in Upcoming Investor Conferences

Nov 5, 2025, 7:01 AM EST - 8 months ago

MindMed to Participate in Upcoming Investor Conferences


MindMed to Report Q3 2025 Financial Results on November 6, 2025

Oct 30, 2025, 4:01 PM EDT - 8 months ago

MindMed to Report Q3 2025 Financial Results on November 6, 2025


Mind Medicine (MindMed) Inc. Announces Proposed Public Offering

Oct 29, 2025, 4:01 PM EDT - 8 months ago

Mind Medicine (MindMed) Inc. Announces Proposed Public Offering


MindMed to Participate in September Investor Conferences

Aug 28, 2025, 7:00 AM EDT - 11 months ago

MindMed to Participate in September Investor Conferences


Definium Therapeutics Earnings Call Transcript: Q2 2025

Jul 31, 2025, 4:30 PM EDT - 1 year ago

Definium Therapeutics Earnings Call Transcript: Q2 2025


Definium Therapeutics Quarterly report: Q2 2025

Jul 31, 2025, 4:30 PM EDT - 1 year ago

Definium Therapeutics Quarterly report: Q2 2025


Definium Therapeutics Earnings release: Q2 2025

Jul 31, 2025, 4:30 PM EDT - 1 year ago

Definium Therapeutics Earnings release: Q2 2025


Definium Therapeutics Slides: Q2 2025

Jul 31, 2025, 4:30 PM EDT - 1 year ago

Definium Therapeutics Slides: Q2 2025


Definium Therapeutics Transcript: AGM 2025

Jun 12, 2025, 10:00 AM EDT - 1 year ago

Definium Therapeutics Transcript: AGM 2025


MindMed to Participate in June Investor Conferences

May 28, 2025, 7:00 AM EDT - 1 year ago

MindMed to Participate in June Investor Conferences


Definium Therapeutics Earnings Call Transcript: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Definium Therapeutics Earnings Call Transcript: Q1 2025


Definium Therapeutics Quarterly report: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Definium Therapeutics Quarterly report: Q1 2025


Definium Therapeutics Earnings release: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Definium Therapeutics Earnings release: Q1 2025


Definium Therapeutics Slides: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Definium Therapeutics Slides: Q1 2025


Definium Therapeutics Proxy statement: Proxy Filing

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Definium Therapeutics Proxy statement: Proxy Filing


Definium Therapeutics Proxy statement: Proxy Filing

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Definium Therapeutics Proxy statement: Proxy Filing


MindMed Appoints Matt Wiley as Chief Commercial Officer

Mar 17, 2025, 7:00 AM EDT - 1 year ago

MindMed Appoints Matt Wiley as Chief Commercial Officer


MichaelNaussCMT
MichaelNaussCMT Jul. 4 at 3:58 PM
$DFTX dropping hints. Now that they a ton of cash I wouldn’t be suprised to see more things researched.
1 · Reply
zcurrency
zcurrency Jul. 4 at 2:58 PM
0 · Reply
IEN
IEN Jul. 4 at 11:16 AM
0 · Reply
Rocketzz
Rocketzz Jul. 4 at 6:58 AM
1 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Jul. 3 at 2:36 PM
The $XBI is up 24.5% the last 15 trading sessions (since 6/10/2026). Investors may recall 4 years ago this time when the XBI surged 31.6% between 6/14/22 & 7/6/22. Excluding the market recovery during COVID in 2020, there's only 2 other times the XBI surged like this (15 day period ending 1/16/19 & before Thanksgiving back in 16). The XBI is almost at its record high. It traded at over $160 for 11 days back in early 2021 Recall it was May 12, 2026 when Dr. Makary resigned. Since then the FDA has reversed course on a number of bio's potential. Attached are the biggest gainers over the last 15 days (60% of more). $RGNX has overwhelmingly been the biggest winner now that they will refile for Navsunli approval in Q326. $SLS doubled again. Short interest is 36% per Seeking Alpha. At a $3B market cap SLS trades @ 4.3X Year 4 (FY30) revenue (from 1 analyst). We though we were smart when we sold SLS in the mid $4 range back in January. $DFTX reported its P3 win 6/22/26 $MRNA we have friends there :)
0 · Reply
MorganHoratio
MorganHoratio Jul. 2 at 10:12 PM
One of the strongest sectors outside of AI right now is Biotech. Neurology $DFTX Definium Therapeutics $CMPS COMPASS Pathways $DNLI Denali Therapeutics $XENE Xenon Pharmaceuticals $NBIX Neurocrine Biosciences The 70% correction trap is driving smart money into neuro-therapeutic CNS alpha pipelines. Elite institutions deploy tactical limit entries atop long-term FIB floors, lock-floating neurological monopolies. Disrupter DFTX accelerates right-side PEG defense, surging on its upsized $805M public offering and pivotal Phase 3 depression data catalysts. It pairs with psychedelic pioneer CMPS at key FIB accumulation zones, while blood-brain-barrier innovator DNLI scales following fresh Russell growth index flows. Flanking them are commercial powerhouse BIIB and pipeline leader XENE hardening their valuation ceilings. Technical compression means nothing without clinical milestones. Facing this neuro-rotation, are you buying the FIB support floors on DFTX and CMPS or resting in defensive cash?
1 · Reply
twiggs462
twiggs462 Jul. 2 at 9:03 PM
$DFTX $CMPS from a couple days ago, but nice to see the coverage https://youtu.be/srT4HUojtFU?t=277&is=5X6xYSBewrec4r2s
0 · Reply
Roaringlegend
Roaringlegend Jul. 2 at 8:42 PM
$WEN got the crowd. $BYND showed what a beaten-down name can do. $SOUN has the AI hype. But $JACK has the cleaner squeeze mechanics: tiny cap, small share count, high short interest, high days-to-cover, and strong recovery after the shakeout. Hype finds the loudest ticker first. Then it finds the best setup. $DFTX
0 · Reply
jmash
jmash Jul. 2 at 5:54 PM
$ATAI $CMPS $DFTX does explain the pop?
1 · Reply
stoxx0007
stoxx0007 Jul. 2 at 4:36 PM
0 · Reply
twiggs462
twiggs462 Jul. 2 at 4:20 PM
$DFTX $ATAI $CMPS Bipartisan Congressional Bill Would Codify Trump’s Psychedelics Order Into Law https://www.marijuanamoment.net/bipartisan-congressional-bill-would-codify-trumps-psychedelics-order-into-law/ H.R.9559 - To accelerate the development of, and access to, psychedelic drugs that could save lives and reverse the crisis of serious mental illness in the United States, and for other purposes. https://www.congress.gov/bill/119th-congress/house-bill/9559 Helps with DEA rescheduling visibility, manufacturing quotas, controlled distribution, clinical site expansion, VA-related treatment pathways, and broader institutional comfort around psychedelic medicine. This is also the kind of policy shift that big pharma pays attention to. A late-stage drug with strong data is one thing. A late-stage drug with improving federal policy, potential priority voucher support, and clearer post-approval scheduling rules is much easier to underwrite. Bullish for the whole sector.
1 · Reply
bl0mkv1st
bl0mkv1st Jul. 2 at 1:43 PM
$DFTX Back to 25....
3 · Reply
Defen
Defen Jul. 2 at 2:00 AM
$DFTX did I miss something today or is the profit taking
1 · Reply
SuperGreenToday
SuperGreenToday Jul. 1 at 8:14 PM
$DFTX Share Price: $43.43 Contract Selected: Dec 18, 2026 $45 Calls Buy Zone: $8.16 – $10.08 Target Zone: $13.11 – $16.02 Potential Upside: 52% ROI Time to Expiration: 169 Days | Updates via https://fxcapta.com/stockinfo/
1 · Reply
twiggs462
twiggs462 Jul. 1 at 7:53 PM
$DFTX Raising the Bar: A Higher Standard for Mental Health Care This is the latest edition of Forward Focus, a regular feature exploring the future of mental health with precision and purpose. Psychiatry is at an inflection point. https://www.linkedin.com/pulse/raising-bar-higher-standard-mental-health-care-definiumtherapeutics-apnme/
0 · Reply
smile696
smile696 Jul. 1 at 7:01 PM
$DFTX Less than 2 million volume.
0 · Reply
Rocketzz
Rocketzz Jul. 1 at 6:27 PM
$DFTX bounce here to $60
0 · Reply
twiggs462
twiggs462 Jul. 1 at 6:26 PM
$DFTX LSD therapy biotech Definium fends off trade-secret lawsuit https://www.reuters.com/legal/litigation/lsd-therapy-biotech-definium-fends-off-trade-secret-lawsuit-2026-07-01/?utm_source=chatgpt.com
0 · Reply
MichaelNaussCMT
MichaelNaussCMT Jul. 1 at 5:10 PM
$DFTX Correct
1 · Reply
BobbyCucumber
BobbyCucumber Jul. 1 at 5:09 PM
0 · Reply
brunoq14
brunoq14 Jul. 1 at 3:04 PM
$DFTX GAD results any day now. Early Q3.
0 · Reply
Rocketzz
Rocketzz Jul. 1 at 2:47 PM
$DFTX what is this color
0 · Reply